SEA Health has inaugurated its new corporate interview series, beginning with a spotlight feature on Dr Yan Xiaojun, Co-founder and Chief Technology Officer (CTO) of CytoNiche Biotech. The interview highlights the company's pivotal role in supporting the commercial success of "Amimestrocel Injection", recognised as China's first allogeneic mesenchymal stromal cell (MSC) drug to gain market approval. 

Founded in 2018, CytoNiche Biotech emerged directly from the scientific achievements of Tsinghua University, established by the research team led by Professor Du Yanan from the School of Medicine. The company benefits from both Tsinghua University's equity participation and support, ensuring its core technologies are rooted in high-level academic research transformation. As a national high-tech enterprise, CytoNiche specialises in the large-scale production of high-quality three-dimensional (3D) cells. The company's mission is to provide integrated, customised cell expansion solutions built on its proprietary 3D microcarriers. CytoNiche's primary achievement lies in creating an independently controllable 3D cell manufacturing platform. The platform achieves large-scale, automated, intelligent, and enclosed production of cell therapies and their derivatives. The firm is actively committed to assisting its global clientele in establishing internationally leading cell therapy production lines, underscoring its role as a key technological partner in accelerating the commercialisation of regenerative medicine. 

（Image Created with Microsoft Designer) 

A Different Path to Scale: The Genesis of 3D TableTrix™ Technology 

While the U.S. market saw its first approved Mesenchymal Stromal Cell (MSC) therapy, Ryoncil, produced via traditional two-dimensional (2D) planar culture, a fundamentally more scalable and efficient paradigm has powered Asia's landmark achievement: the production of the MSC therapy, "Amimestrocel Injection." The secret lies in a deliberate technological evolution rooted in over a decade of foundational academic research, centred on 3D suspension culture. 

The innovative path to mass production was not an abrupt technical decision but a calculated move tracing back to 2011. The origin lies in the pioneering work of the founding team during their doctoral studies in microtissue engineering. Their initial research focused on integrating multidisciplinary advances—from microfluidics to materials science—to engineer complex, injectable 3D micro-tissues for therapeutic use. The core goal was ambitious: to move beyond flat cell monolayers and create complex, living materials that better mimicked natural tissue architecture and function. 

A critical phase of this early research involved identifying a superior biomaterial as the structural scaffold for these 3D microtissues. The team's exhaustive search ultimately settled on gelatin, a choice driven by its unmatched combination of properties essential for clinical translation: 

1. Proven Safety and Clinical History: As a pharmacopoeia-grade material with a long history of safe use in the human body (e.g., artificial plasma, pharmaceutical capsules), gelatin provided a non-negotiable safety baseline. It is readily metabolised and absorbed in vivo. 
2. Optimal Functionality and Biomimicry: It offers excellent biocompatibility, robust cell adhesion, and controllable degradation kinetics. Its properties make it an ideal matrix for simulating the in vivo microenvironment, providing the cues cells need to grow and function naturally in three dimensions. 

(Image: CytoNiche’s 3D TableTrix™ Microcarriers W01 in tablet and powder form) 

From Lab Breakthrough to Industry Standard 

A promising discovery in early cell therapy research would ultimately redefine an entire approach to manufacturing, as scientists working with 3D TableTrix™ microcarriers observed a profound effect: when cells were cultured on these degradable scaffolds to form 3D microtissues, they demonstrated such potent therapeutic efficacy that achieving a comparable effect required only one-tenth of the cell dosage compared to traditional, carrier-free cell injections, thus highlighting a significant therapeutic advantage and the potential for a fundamentally more efficient production paradigm. 

However, translating this potent laboratory discovery into a reliable, commercially viable product demanded solving complex engineering puzzles. Leveraging its chemical engineering expertise, the founding team successfully shifted its mission from proof-of-concept to tackling the challenges of low-cost, large-scale production, culminating in the establishment of stable, commercial-scale production of the 3D TableTrix™ microcarriers as pharmaceutical raw materials. 

（Image: Unique Features of CytoNiche’s 3D TableTrix™ Microcarriers) 

Aligning with Social Value 

The 2016 Wei Zexi Incident, a period of extreme regulatory turbulence, forged the commercial viability of CytoNiche Biotech's 3D manufacturing platform. The 2016 scandal, involving a student’s death after receiving an unproven and aggressively marketed cell therapy, exposed critical gaps in China's healthcare oversight and sparked a national outcry for reform. The intense scrutiny that followed prompted a rapid, comprehensive tightening of regulations, culminating in the 2017 Technical Guidelines, which explicitly classified cell therapies as pharmaceutical drugs and mandated rigorous clinical and manufacturing standards. 

Faced with this foundational shift, CytoNiche Biotech undertook a profound strategic realignment of its business model. The company faced a clear fork in the road: become a high-profit cell therapy drug developer, or transition to an upstream platform technology enabler. This decision stemmed from a clear judgment: providing upstream platform technologies could systematically empower hundreds of cell therapy enterprises, fundamentally reducing R&D and production costs across the entire industry. The choice also directly reflects the founding team's ethos and Tsinghua University’s pursuit of "advancing knowledge while serving society", prioritising broad societal value and industry enablement above purely commercial profit.  

The Commercial Feasibility Hurdle 

A 2018 study in the Biochemical Engineering Journal threw a curveball at conventional bioprocessing wisdom. The paper compared four technologies for expanding umbilical cord-derived mesenchymal stem cells (MSCs). The conclusion was surprising: for commercial feasibility, traditional multi-layer flasks ranked first in cost-effectiveness, with stirred-tank bioreactors—the workhorse of biologics manufacturing—second. This finding challenged the established belief that bioreactor-based systems, crucial for vaccines and proteins, would automatically be the most economical path for cell therapies. 

Theoretically, microcarriers offer the perfect solution for large-scale adherent cell culture. With a high surface-area-to-volume ratio, they promised to grow vastly more cells in less space than 2D flasks. They could be used in scalable, automated bioreactors, potentially slashing labour, material, and facility costs. Yet, in-depth analysis revealed a critical bottleneck in existing technology: 

1. Challenge: Using traditional non-degradable microcarriers faced significant challenges in efficient separation during cell harvesting. 
2. Impact: This inefficiency drastically increased overall production costs. Cell recovery rates languished at 50–60% (far lower than the 90% achievable in 2D culture), and downstream processing time ballooned by 3–4 times. 

This analysis cemented the strategic value of CytoNiche's core technology: the degradable properties of the 3D TableTrix™ microcarriers fundamentally resolved the cell harvesting challenge. By enabling highly efficient and gentle cell recovery, the technology eliminates the costly time and material waste associated with non-degradable platforms, thereby significantly reducing overall production costs. 

 CytoNiche’s Solution: Degradation and Automation 

CytoNiche's core technology, the degradable 3D TableTrix™ microcarriers, fundamentally resolves this issue. By enabling highly efficient, gentle cell recovery, the technology eliminates the costly time, labour, and material waste associated with non-degradable platforms.  

This technological fix, combined with automation, provides a key solution for scalable production: 

1. Massive Space Reduction: The new method reduces the required production space from several thousand square meters of high-standard Grade B/A cleanrooms to just over a hundred square meters of a standard Grade C laboratory environment. 
2. Cost Control: This dramatically lowers facility construction costs, energy consumption, and microbial contamination risks, while simultaneously reducing reliance on manual labour. The process strikes an optimal balance between ensuring quality and yield, and minimising costs. 

(Image: Impact of 3D Platform: Key Efficiency & Recovery Metrics) 

The Profound Impact on Drug Pricing 

A direct data comparison reveals the profound value of this manufacturing efficiency in the market: 

Assuming similar gross margins, calculations suggest that the unit production cost of the Amimestrocel Injection (MSC), which uses a higher cell count and the CytoNiche 3D process, is nearly 1/70 that of the U.S.-approved product. This manufacturing revolution is positioned to make advanced regenerative medicine therapies accessible on a massive scale. 

The Billion-Scale Cell Manufacturing System 

The 3D degradable microcarrier-based suspension culture process achieves a substantial cost differential, validating its immense advantages in efficiency and scalability and establishing the crucial industrial foundation for making cell therapies globally widely accessible and affordable. This success confirms the 3D platform as the key tool for transitioning pioneering cell therapies from the lab bench to billion-scale commercial production.

CytoNiche fully substantiated this revolutionary 3D manufacturing process through real-world application with a key downstream partner, successfully facilitating a process change for a therapy already in Phase III clinical trials. They submitted comprehensive comparability study data to the NIFDC, definitively proving that cells produced via the 3D culture process are equivalent in quality and function to those from the traditional, less-scalable 2D process. Furthermore, the collaboration helped establish new quality control standards for carrier degradation residues, contributing to the regulatory maturity of the field. Ultimately, the integrated process solutions and equipment provided by CytoNiche acted as the essential enabling technology, successfully supporting their partner in obtaining market approval and confirming the 3D platform as a global model for industrialising regenerative medicine. 

References 

Stepping into Huakan Biotechnology, Engaging with the Power of Innovation — Unveiling the Leader in 3D Cell Manufacturing. (2025, December). SEA Health. 

https://mp.weixin.qq.com/s/n5X0cLF-D1hDNX0vu0cjUA